Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
45.1M
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
21.2M
-
Shares change
-
+137K
-
Total reported value, excl. options
-
$814M
-
Value change
-
+$2.71M
-
Number of buys
-
49
-
Number of sells
-
-47
-
Price
-
$38.39
Significant Holders of Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) as of Q3 2020
115 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q3 2020.
Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.2M shares
of 45.1M outstanding shares and own 47.03% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (2.66M shares), BlackRock Inc. (2.35M shares), Sofinnova Investments, Inc. (2.19M shares), Cormorant Asset Management, LP (1.4M shares), VANGUARD GROUP INC (1.24M shares), FMR LLC (1.11M shares), STATE STREET CORP (1.05M shares), ALLIANCEBERNSTEIN L.P. (960K shares), LOOMIS SAYLES & CO L P (789K shares), and GOLDMAN SACHS GROUP INC (726K shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.